10 Best Low Priced Biotech Stocks to Buy Now

3. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)

Stock Price: $1.75

Number of Hedge Fund Holders: 44

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is a biopharmaceutical company that develops and commercializes cell therapies as novel cancer immunotherapy products. Its lead product candidate is LN-144, an autologous adoptive cell therapy for metastatic melanoma. The company ranks third on our list of the top low-priced biotech stocks to invest in now.

On May 8, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) reported its fiscal Q1 2025 earnings, with total product revenue reaching $49.3 million. The company also revised its full-year revenue guidance of $250 million to $300 million, down from the previous range of $450 million – $475 million. It is also expecting regulatory approvals for its product Amtagvi, that treats a type of skin cancer, in Canada, the EU, and the UK.

Although Iovance Biotherapeutics Inc. (NASDAQ:IOVA) underwent a net loss of $116.2 million in fiscal Q1 2025, it maintained a strong cash position of $366 million. Management expects it to fund operations well into H2 2026, bringing a positive light to its operations. It is also expanding its treatment network and manufacturing capacity, with more than 80 US ATCs and plans for international market expansion.

In light of such favorable conditions, Mizuho Securities analyst Salim Syed maintained a Buy rating on Iovance Biotherapeutics Inc. (NASDAQ:IOVA) on May 9, setting a price target of $10.00.